Thus, the refinement of a selection of biomarkers for AKT inhibitors is needed to improve their monotherapy activity. mutation was identified as a probable oncogenic driver in patients, indicating that the inhibition of AKT1 presents a novel and specific drug target in this disease [5,6]. the 78 patients enrolled,...